Extraordinary presentations based on art. 53LR
-
Unaudited financial position as of March 31, 2024. Required for future bondholders meeting.Currently available on his website for the company
-
A bondholder meeting is currently scheduled for early May as the company continues its dialogue with bondholders.
Allschwil, Switzerland – April 17, 2024
Idorsia Ltd (SIX: IDIA) today announced that its unaudited financial position as of March 31, 2024, required for the upcoming meeting of bondholders, is available on the company's website at the following link : http://www.idorsia.com/investors/financial information
Idorsia continues to engage with bondholders regarding options and terms for the repayment of the convertible notes, which mature on July 17, 2024 (ISIN: CH0426820350). As a result, the bondholders' meeting, originally scheduled for April 30, 2024, will now be held shortly thereafter.
Chief Financial Officer Andre C. Muller commented:
“We have had a number of communications with noteholders over the past week. Taking into account the needs of noteholders and our objective to avoid unnecessary dilution, we have proposed amendments to the terms of the notes. We are making final decisions and will be issuing invitations to the bondholder meeting in the coming days.”
Note to editor
About Idorsia
Idorsia Ltd aims to do more – we have more ideas, see more opportunities and want to help more patients. To achieve this, we will develop Idorsia into a leading biopharmaceutical company with a strong scientific core.
Headquartered near Basel, Switzerland, the biotechnology capital of Europe, Idorsia specializes in the discovery, development and commercialization of small molecules that change the horizon of treatment options. Idorsia has a 25-year heritage in drug discovery, an extensive portfolio of innovative medicines in the pipeline, an experienced team of experts from bench to bedside, and commercial operations in Europe and North America. This makes them an ideal group to bring innovative medicines to the world. To the patient.
Idorsia was listed on the Swiss SIX stock exchange (ticker symbol: IDIA) in June 2017 and has over 750 highly qualified specialists dedicated to realizing our ambitious goals.
Please contact us for more information.
Andrew C. Weiss
Senior Vice President, Head of Investor Relations and Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com
The above information contains certain forward-looking statements regarding the Company's business that we “estimate,'' “believe,'' “expect,'' “may,'' and “may.'' You can identify them by the use of forward-looking terminology, such as the forward-looking terminology such as “the future of the future.” “expected”, “will”, “continue”, “should”, “will”, “seek”, “pending”, or “anticipated” or similar expressions. , or by discussion of strategies, plans, or intentions. Such statements include a description of the Company's investment and research and development programs and anticipated expenditures related thereto, a description of any new products the Company expects to introduce, such products and products in the Company's existing portfolio; Contains expected customer demand for. Such statements reflect the Company's current views regarding future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. . If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, actual results may differ from those projected, believed or estimated herein. It could be very different from what you expected.
attachment
